{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031599","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.146443+00:00","generated_at":"2026-06-21T21:35:38.868185+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abeona Q3 net loss $9.5M; Phase 3 EB-101 meets endpoints, BLA submission planned Q2 2023","bullets":["Net loss of $9.5M ($1.48 loss per share) for Q3 2022, compared to $7.0M loss in Q3 2021.","Cash, equivalents and investments totaled $23.5M at Sept 30, 2022; subsequent $35M private placement extends runway into Q3 2024.","Phase 3 VIITAL trial of EB-101 for RDEB met both co-primary endpoints with statistically significant wound healing and pain reduction.","Company plans to submit BLA to FDA for EB-101 in Q2 2023; possible Priority Review Voucher eligibility upon approval.","R&D expenses decreased to $5.5M from $9.1M year-over-year; G&A expenses down to $3.9M from $5.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031599","json":"https://secwatch.observer/filing/0001493152-22-031599.json","markdown":"https://secwatch.observer/filing/0001493152-22-031599.md","text":"https://secwatch.observer/filing/0001493152-22-031599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/0001493152-22-031599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:35:38.868185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6e9181bb4e185a909b1544f6fcf5a8d11b86dcf","claim":"ABEONA THERAPEUTICS INC. reported third quarter of 2022 results: net income $9.5 million, EPS $1.48 loss per common share.","evidence_excerpt":"Net loss attributable to common shareholders for the third quarter of 2022 was $9.5 million, or $1.48 loss per common share as compared to $7.0 million, or $1.80 loss per common share, in the third quarter of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/0001493152-22-031599-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Net income","value":"$9.5 million"},{"label":"EPS","value":"$1.48 loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}